JMP Securities downgraded Adamas Pharmaceuticals from Market Outperform to Market Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2021 | $8.50 | Outperform → Market Perform | Northland Capital Markets |
| 10/12/2021 | Market Outperform → Market Perform | JMP Securities | |
| 10/12/2021 | $7.00 → $8.00 | Overweight → Neutral | Piper Sandler |
| 10/12/2021 | $10.00 → $9.10 | Buy → Neutral | HC Wainwright & Co. |
| 10/11/2021 | Outperform → Market Perform | William Blair |
15-12B - Adamas Pharmaceuticals Inc (0001328143) (Filer)
EFFECT - Adamas Pharmaceuticals Inc (0001328143) (Filer)
S-8 POS - Adamas Pharmaceuticals Inc (0001328143) (Filer)
4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)
4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)
4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)
ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). "Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "In addition, the acquisition adds a new growth catalyst, diversifies our revenue base and cash flow, and is expected to be significantly accretive in 2022." Compelling Strategic Rationale Strengthens Parkinson's disease portfolio with GOCOVRI® (amantadine) extended r
Acquisition of two marketed products diversifies and accelerates revenue and cash flowExpected to be significantly accretive in 2022Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastructureTotal consideration up to $9.10 per share. Upfront cash payment of $8.10 per share with fully diluted equity value of approximately $400 million, plus $1.00 contingent value right based on net sales of GOCOVRI®Conference call and webcast today at 8:30 a.m. ET to discuss the transaction ROCKVILLE, Md. and EMERYVILLE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS),
Second quarter 2021 total revenues of $22.0 million, a 17% increase over second quarter 2020 GOCOVRI new paid prescriptions of 730, a 97% increase over second quarter 2020 Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the second quarter ended June 30, 2021, and recent corporate highlights. "We delivered a strong performance in the second quarter, with a robust increase in demand set to fuel future growth," said Neil F. McFarlane, Chief Executive Officer. "We remain on track to achieve our 2021 goals as we navigate the
ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). "Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "In addition, the acquisition adds a new growth catalyst, diversifies our revenue base and cash flow, and is expected to be significantly accretive in 2022." Compelling Strategic Rationale Strengthens Parkinson's disease portfolio with GOCOVRI® (amantadine) extended r
ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus' proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) expired at 11:59 p.m. on November 22, 2021. On October 21, 2021, Supernus and Adamas filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice. The expiration of the HSR Act waiting period satisfies one of the conditions to consummate the Offer (as defined below). The Off
Acquisition of two marketed products diversifies and accelerates revenue and cash flowExpected to be significantly accretive in 2022Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastructureTotal consideration up to $9.10 per share. Upfront cash payment of $8.10 per share with fully diluted equity value of approximately $400 million, plus $1.00 contingent value right based on net sales of GOCOVRI®Conference call and webcast today at 8:30 a.m. ET to discuss the transaction ROCKVILLE, Md. and EMERYVILLE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS),
Northland Capital Markets downgraded Adamas Pharmaceuticals from Outperform to Market Perform and set a new price target of $8.50
JMP Securities downgraded Adamas Pharmaceuticals from Market Outperform to Market Perform
Piper Sandler downgraded Adamas Pharmaceuticals from Overweight to Neutral and set a new price target of $8.00 from $7.00 previously
SC 13G/A - Adamas Pharmaceuticals Inc (0001328143) (Subject)
SC 13G/A - Adamas Pharmaceuticals Inc (0001328143) (Subject)
SC 13D - Adamas Pharmaceuticals Inc (0001328143) (Subject)